Found: 205
Select item for more details and to access through your institution.
Will deciphering the epidermal 'ménage à trois' lead to predictive biomarkers for childhood atopic dermatitis?
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 9, p. 1679, doi. 10.1111/jdv.20180
- By:
- Publication type:
- Article
725 - The TCS/TCI-free rate remains high and stable while on lebrikizumab for treatment of moderate-to-severe atopic dermatitis over 1 year.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.098
- By:
- Publication type:
- Article
630 - Efficacy comparison of targeted systemic monotherapies including lebrikizumab for moderate-to-severe atopic dermatitis: a network meta-analysis.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.014
- By:
- Publication type:
- Article
732 - EASI 90 response sustained up to 38 weeks after lebrikizumab withdrawal despite negligible serum concentrations.
- Published in:
- British Journal of Dermatology, 2024, v. 191, p. 1, doi. 10.1093/bjd/ljae266.105
- By:
- Publication type:
- Article
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs.
- Published in:
- Allergy, 2024, v. 79, n. 6, p. 1501, doi. 10.1111/all.16009
- By:
- Publication type:
- Article
The vIGA‐AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema Council.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 3, p. e291, doi. 10.1111/jdv.19627
- By:
- Publication type:
- Article
Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii8, doi. 10.1093/bjd/ljad498.010
- By:
- Publication type:
- Article
Incidence of venous thromboembolic events and atherosclerotic cardiovascular disease risk factors in adolescents and adults with atopic dermatitis in Denmark: a population-based cohort study.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii36, doi. 10.1093/bjd/ljad498.038
- By:
- Publication type:
- Article
Stationäre Psoriasistherapie: Quo vadis? – Eine retrospektive Studie an den Universitätskliniken Aachen, Bonn und Essen im Zeitraum von 2010 bis 2019.
- Published in:
- Die Dermatologie, 2024, v. 75, n. 2, p. 170, doi. 10.1007/s00105-023-05234-2
- By:
- Publication type:
- Article
Electrical impedance spectroscopy detects skin barrier dysfunction in childhood atopic dermatitis.
- Published in:
- Allergy, 2024, v. 79, n. 1, p. 142, doi. 10.1111/all.15895
- By:
- Publication type:
- Article
Development of a clinical algorithm to predict phenotypic switches between atopic dermatitis and psoriasis (the "Flip‐Flop" phenomenon).
- Published in:
- Allergy, 2024, v. 79, n. 1, p. 164, doi. 10.1111/all.15921
- By:
- Publication type:
- Article
Evidence for a restoration of TLR2 response in epidermal dendritic cells in atopic dermatitis by topical anti‐inflammatory therapy.
- Published in:
- Allergy, 2024, v. 79, n. 1, p. 249, doi. 10.1111/all.15899
- By:
- Publication type:
- Article
Immunoglobulin E autoantibodies in atopic dermatitis associate with Type‐2 comorbidities and the atopic march.
- Published in:
- Allergy, 2023, v. 78, n. 12, p. 3178, doi. 10.1111/all.15822
- By:
- Publication type:
- Article
Tralokinumab therapy for moderate‐to‐severe atopic dermatitis: Clinical outcomes with targeted IL‐13 inhibition.
- Published in:
- Allergy, 2023, v. 78, n. 11, p. 2875, doi. 10.1111/all.15811
- By:
- Publication type:
- Article
Efficacy and Safety of Methotrexate in Psoriasis Vulgaris Long-Term Treatment: A Real-World Observation Study.
- Published in:
- Indian Journal of Dermatology, 2023, v. 68, n. 6, p. 669, doi. 10.4103/ijd.ijd_551_23
- By:
- Publication type:
- Article
Psoriatic arthritis or osteoarthritis? Data from a specialized dermatological–rheumatological collaboration—the Psoriatic Arthrtis Center Bonn.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 11, p. e1348, doi. 10.1111/jdv.19320
- By:
- Publication type:
- Article
A detailed look at the European Medicines Agency's recommendations for use of Janus kinase inhibitors in patients with atopic dermatitis.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 10, p. 2041, doi. 10.1111/jdv.19255
- By:
- Publication type:
- Article
Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 5, p. 753, doi. 10.1007/s40257-023-00793-5
- By:
- Publication type:
- Article
A concept for integrated care pathways for atopic dermatitis—A GA<sup>2</sup>LEN ADCARE initiative.
- Published in:
- Clinical & Translational Allergy, 2023, v. 13, n. 9, p. 1, doi. 10.1002/clt2.12299
- By:
- Publication type:
- Article
Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 8, p. 3574, doi. 10.1007/s12325-023-02528-8
- By:
- Publication type:
- Article
Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 8, p. 881, doi. 10.1093/ced/llad129
- By:
- Publication type:
- Article
Dermatomyositis autoantigen CHD4 forms immune stimulatory complexes with endogenous DNA.
- Published in:
- Experimental Dermatology, 2023, v. 32, n. 7, p. 965, doi. 10.1111/exd.14799
- By:
- Publication type:
- Article
Treatment of chronic nodular prurigo with intravenous naloxone during pregnancy.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 7, p. e912, doi. 10.1111/jdv.19016
- By:
- Publication type:
- Article
400 Efficacy of lebrikizumab in patients who did not achieve protocol-defined criteria for response after initial 16 weeks of therapy.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.023
- By:
- Publication type:
- Article
427 Long-term 4-year safety of upadacitinib in moderate-to-severe atopic dermatitis: results of an integrated analysis of phase 3 studies.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.047
- By:
- Publication type:
- Article
392 Safety of amlitelimab in a Phase 2a clinical trial of patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.017
- By:
- Publication type:
- Article
IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis.
- Published in:
- Allergy, 2023, v. 78, n. 6, p. 1554, doi. 10.1111/all.15647
- By:
- Publication type:
- Article
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 6, p. 740, doi. 10.1093/bjd/ljad022
- By:
- Publication type:
- Article
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 4, p. 1867, doi. 10.1007/s12325-023-02445-w
- By:
- Publication type:
- Article
Spesolimab, an anti‐interleukin‐36 receptor antibody, in patients with moderate‐to‐severe atopic dermatitis: Results from a multicentre, randomized, double‐blind, placebo‐controlled, phase IIa study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 3, p. 549, doi. 10.1111/jdv.18727
- By:
- Publication type:
- Article
322 Efficacy and safety of lebrikizumab in moderateto-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2).
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii12, doi. 10.1093/bjd/ljac140.018
- By:
- Publication type:
- Article
345 Treatment with amlitelimab—a novel nondepleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii33, doi. 10.1093/bjd/ljac140.039
- By:
- Publication type:
- Article
353 Amlitelimab reduces serum IL-13 in a phase 2a clinical trial in atopic dermatitis without impacting T-cell expansion in a T-cell recall assay.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. ii39, doi. 10.1093/bjd/ljac140.045
- By:
- Publication type:
- Article
The abundance of Ruminococcus bromii is associated with faecal butyrate levels and atopic dermatitis in infancy.
- Published in:
- Allergy, 2022, v. 77, n. 12, p. 3629, doi. 10.1111/all.15440
- By:
- Publication type:
- Article
A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Therapeutic management and clinical remission for patients with psoriasis and psoriatic arthritis in a specialized dermatological‐rheumatological center.
- Published in:
- Dermatologic Therapy, 2022, v. 35, n. 10, p. 1, doi. 10.1111/dth.15755
- By:
- Publication type:
- Article
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate‐to‐severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo‐controlled, phase III clinical trial (BREEZE‐AD4)*
- Published in:
- British Journal of Dermatology, 2022, v. 187, n. 3, p. 338, doi. 10.1111/bjd.21630
- By:
- Publication type:
- Article
From Skin Barrier Dysfunction to Systemic Impact of Atopic Dermatitis: Implications for a Precision Approach in Dermocosmetics and Medicine.
- Published in:
- Journal of Personalized Medicine, 2022, v. 12, n. 6, p. 893, doi. 10.3390/jpm12060893
- By:
- Publication type:
- Article
Bullous Pemphigoid in Patients Receiving Immune-Checkpoint Inhibitors and Psoriatic Patients—Focus on Clinical and Histopathological Variation.
- Published in:
- Dermatopathology, 2022, v. 9, n. 1, p. 60, doi. 10.3390/dermatopathology9010010
- By:
- Publication type:
- Article
Telephone follow‐up for monitoring of complications and boosting patient satisfaction after inpatient dermatosurgery: a prospective two‐center study.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2022, v. 20, n. 1, p. 121, doi. 10.1111/ddg.14648
- By:
- Publication type:
- Article
Poststationäre telefonische OP‐Nachsorge zur Erfassung von Komplikationen und Steigerung der Patientenzufriedenheit nach dermatochirurgischen Eingriffen: Eine prospektive bizentrische Studie.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2022, v. 20, n. 1, p. 121, doi. 10.1111/ddg.14648_g
- By:
- Publication type:
- Article
Annular plaques mimicking Rowell's syndrome in the course of coronavirus disease 2019 mRNA vaccines: An overlooked phenomenon?
- Published in:
- Journal of Dermatology, 2022, v. 49, n. 1, p. 151, doi. 10.1111/1346-8138.16210
- By:
- Publication type:
- Article
Machine Learning-Based Deep Phenotyping of Atopic Dermatitis: Severity-Associated Factors in Adolescent and Adult Patients.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Specialized dermatological-rheumatological patient management improves diagnostic outcome and patient journey in psoriasis and psoriatic arthritis: a four-year analysis.
- Published in:
- BMC Rheumatology, 2021, v. 5, n. 1, p. 1, doi. 10.1186/s41927-021-00217-z
- By:
- Publication type:
- Article
Specialized dermatological-rheumatological patient management improves diagnostic outcome and patient journey in psoriasis and psoriatic arthritis: a four-year analysis.
- Published in:
- BMC Rheumatology, 2021, v. 5, n. 1, p. 1, doi. 10.1186/s41927-021-00217-z
- By:
- Publication type:
- Article
Serum receptor activator of nuclear factor kappa‐Β ligand/osteoprotegerin ratio correlates with severity and suggests fracture's risk in older women with atopic dermatitis.
- Published in:
- Allergy, 2021, v. 76, n. 10, p. 3220, doi. 10.1111/all.14971
- By:
- Publication type:
- Article
Tralokinumab in atopic dermatitis.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2021, v. 19, n. 10, p. 1435, doi. 10.1111/ddg.14545
- By:
- Publication type:
- Article
Tralokinumab bei atopischer Dermatitis.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2021, v. 19, n. 10, p. 1435, doi. 10.1111/ddg.14545_g
- By:
- Publication type:
- Article
Cutaneous Adverse Reactions to COVID-19 Vaccines: Insights from an Immuno-Dermatological Perspective.
- Published in:
- Vaccines, 2021, v. 9, n. 9, p. 944, doi. 10.3390/vaccines9090944
- By:
- Publication type:
- Article